Prevnar 13 Loses ‘Routine’ Endorsement For Older Adults In CDC Panel Vote

ACIP still supports use of Pfizer’s pneumococcal vaccine in immunocompetent individuals ages 65 years and older based on shared clinical decision-making, but concludes that routine immunization is no longer warranted due to herd effect from pediatric vaccination.

Streptococcus pneumoniae or pneumococcus bacterias. 3d illustration - Illustration
ACIP voted to move away from routine use of Prevnar 13 in older adults to prevent invasive disease caused by Streptococcus pneumoniae. • Source: Shutterstock

A US advisory panel has dialed back its current recommendation for routine immunization of older adults with Pfizer Inc.’s Prevnar 13 but is not proposing to entirely eliminate use of the pneumococcal 13-valent conjugate vaccine in this age group.

In a compromise vote that followed unsuccessful votes on two prior proposals, 13 of 14 members of the Advisory Committee...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet